The cannabis plant is known to contain at least 113 different cannabinoids, chemical compounds that interact with our human endocannabinoid system and provide many benefits for the body and mind and general health. You've probably heard of CBD and THC, the cannabinoids most abundant in the cannabis plant. But there are other secondary compounds that occur in smaller amounts and have attracted more and more attention in recent years because of their possible applications.
For the Kannabia Seed Company, we are always at the vanguard when it comes to selecting new marijuana strains, and we try to provide home growers with novel genotypes that allow maximization of the proportion of those cannabinoids that are currently most in demand on the market. These are varieties that were previously almost unavailable, with CBG, THCV or CBDV values that were reserved for scientific genetic laboratories.
Thanks to the selection of specific phenotypes according to certain genetic characteristics, we have managed to bring to market strains with a negligible amount of THC (less than 0.3%), which is why this type of cannabis is legal in most states. At the same time, we have increased the proportion of other secondary cannabinoids and these have a lot to offer both recreational consumers and medical users.
So if you are looking for marijuana strains with a high cannabinoid content other than THC, which open up a whole new spectrum of possibilities for growing this plant, then at the Kannabia Seed Company we have a wide range of options available for you. They are sure to surprise you, both for their novelty and for their confirmed quality.
The phytocannabinoids (phyto = plant) interact with the human body via the endocannabinoid system, which is responsible for controlling areas such as sleep, immune system or mood. The cannabinoids develop their effect by coupling to specific cannabinoid receptors that are located on the surface of the cells. These receptors “eavesdrop” on conditions outside the cell and relay information about these changing conditions to the inside of the cell, triggering an appropriate response. The receptors are located in different locations of the central (or peripheral) nervous system, with the two main types called CB1 and CB2.
So imagine that your endocannabinoid system has a series of “parking spaces” labeled CB1 or CB2. Each type of cannabinoid prefers to “park” at a certain type of receptor and the more receptors used, the more beneficial this will be for the body and mind.
This helps us to understand the theory of the “entourage effect”, which assumes a joint synergistic action of several components of the plant (cannabinoids, terpenes…) in order to mutually increase their properties and thus achieve a stronger effect of each component, stronger than when taking the substance in question in isolation.
CBD (Cannabidiol) has been the cannabinoid star in recent years, breaking down the walls of prohibition and contributing to the general acceptance of cannabis in the therapeutic area. Although it was first isolated in the early 1940s, its anticonvulsant properties did not attract the interest of scientists until the 1960s.
It was only since the turn of the millennium that it became the subject of numerous studies that examined its health-promoting properties and confirmed that it was an effective form of treatment for severe cases of epilepsy, as well as anti-inflammatory, analgesic, had anti-anxiety, calming and nausea-reducing properties.
But unlike THC, which causes a significant “high”, CBD is not psychotropic and does not cause euphoria or changes in sensory perception. This has made it a very attractive option for those who want to make cannabis part of their lifestyle to achieve balanced health and well-being.
Research also suggests that CBD may help mitigate some of the most undesirable properties of THC, such as anxiety, paranoia, or impaired cognitive function. That's why CBD-rich strains are an invaluable tool for more tolerable cannabis, conquering not only therapeutic users, but also recreational users who are looking for more easily tolerated marijuana for everyday use.
The growing interest in cannabidiol has led Kannabia's “breeders” to work to create new marijuana strains with a high CBD content. In our catalog you can find various strains with a lot of CBD (up to 10%) and little THC (less than 0.5%). But also balanced strains with a CBD-THC ratio of 2:1 for those who want to enjoy the benefits of the “entourage effect” at its best.
So far, both THC and CBD have been the cannabinoids that have caught the attention of scientists and consumers, but CBG (cannabigerol) is also starting to join this group. Preclinical studies suggest that it may share many positive properties with CBD, as both have antioxidant, neuroprotective and analgesic effects.
Research suggests that CBG has a partial preference for the CB1 and CB2 receptors of the endocannabinoid system, as does THC, which exerts its psychotropic effects through interaction with these receptors. However, CBG has been observed to buffer these psychotropic effects and can even alleviate the feelings of anxiety and paranoia that sometimes accompany the consumption of large amounts of THC.
CBG research is still in a preclinical phase, but existing research suggests that it is a promising therapeutic that may play the next significant role in cannabis-based treatments after the CBD boom. Its painkilling properties can exceed those of THC, but without psychotropic effects. There are also research results that suggest that CBG has anti-cancer and antibacterial qualities.
However, there is a problem with using these positive properties. While CBD and THC occur in amounts of up to 20% of the flower weight, CBG is virtually non-existent in mature cannabis flowers (less than 1%). This means growers need 20 times more biomass to get the same amount of CBD or THC.
Kannabia Seed Company breeders have made genetic selection to increase the concentration of this cannabinoid and obtain better CBG output. The result was a strain like our CBG Auto, a genotype with an incredibly high CBG content of up to 7% and with a very low THC content (below 0.1%), which makes this cannabis legal almost all over the world because it has no psychotropic effects.
These plants are not yet found very often in the seed catalogs, but they are in great demand and are currently being sold on a relatively large scale. grown, parallel to the growing interest in CBG concentrates and distillates from therapeutic research. This makes a new paradigm a reality for both science and home marijuana growers looking for new experiences.
Another emerging trend with much anticipation is THCV (Tetrahydrocannabivarin), a secondary cannabinoid with psychotropic effects that produces a feeling of focused and energetic euphoria, but also has potential therapeutic uses in the Suppression of appetite.
Although the chemical composition of THC and THCV is very similar and the two substances may also have some parallels in psychotropic effects, THCV is a unique cannabinoid because it is a biphasic compound: It also has different effects at different dosages.
At high doses, it acts as a partial agonist (as an activator, but only at low levels) of the CB1 receptor, like THC, causing a psychotropic effect that is described as uplifting, but makes you sharp, focused, very creative and motivated. The effect occurs more quickly, but because THCV does not dock with the CB1 receptor with the same force as THC, it has a shorter duration of action.
In the case of plants with higher THC content, the effects come on more gradually and last longer, a bit like a long-distance cannabis marathon. With THCV, everything is intensity and speed, hence the comparison with the “racing car” among cannabinoids.
At low doses, however, THCV acts as an antagonist (blocker) of the CB1 receptor, so it prevents THC from docking there, reduces the psychotropic effect and increases appetite control because it potentially increases sensitivity to insulin. Although most people associate cannabis with stimulating appetite, THCV may have the opposite effect. For this reason, THCV is promoted as a diet aid or as a therapeutic agent for diabetes or obesity, which is why it has been named the “diet weed.”
The THCV occurs naturally in marijuana only in very small quantities. In the past, varieties with a certain amount of THCV have been difficult to breed and process because of low demand. and the complex process of sorting out were not easy to select.
Nevertheless, at Kannabia, thanks to years of intensive “breeding” and stabilization, we have managed to bring plants to the market that produce an acceptable amount of this substance, specifically with 7% THCV, which is in balance with 7% THC, offering a balanced experience between both cannabinoids and complete control of the psychotropic experience allowed.
Cannabidivarin (CBDV) was identified in the late 1960s, but due to cannabis prohibition it has only recently become the subject of research and has emerged as a powerful anticonvulsant, in addition to other properties that make it a beacon of hope in the medical field.
CBDV is a non-psychotropic compound that will not give you the euphoric high often associated with high-THC cannabis. As for the difference between CBDV and CBD, both substances offer similar positive properties. Nevertheless, cannabidivarin is more suitable for the treatment of neurological disorders and epileptic symptoms, while CBD is often used to treat insomnia, everyday stress, anxiety and similar problems.
But unlike CBD, CBDV is only found in very small amounts in the cannabis plant, which is why it is more expensive to use. If you're looking for high CBDV strains, you'll need to look for pure and unmodified Landrace indicas, but you can also find this cannabinoid in some sativa strains.
Or you can choose our CBDV Auto, which is the fastest way to get this cannabinoid, because thanks to our intensive genetic selection we have been able to release an autoflowering marijuana plant that has the highest cannabidiol and cannabidivarin content currently available on the market combined, with the lowest possible THC content (less than 0.2%) and a CBDV-THC ratio of 25:1, which is why no psychotropic effects are noticeable.
As you can see, at Kannabia Seed Company we are aware of the importance of researching and developing seeds that produce plants with high levels of these new cannabinoids. No longer just CBD plants, where you have a selection that is sure to exceed your expectations, but also plants with those cannabinoids that traditionally did not have the chance to see the light of day because they were only present in very small quantities in marijuana plants.
Thanks to the efforts of our “breeders”, we have managed to increase the content of these cannabinoids to an unprecedented level and thus offer our customers new varieties that would have been impossible to breed a few years ago. And always at the best price on the market for an extremely specific product that not only has a high degree of exclusivity, but also the inherent quality that characterizes our seed bank.
By selecting "Accept all", you give us permission to use the following services on our website: YouTube, Vimeo, ReCaptcha, Google Analytics 4. You can change the settings at any time (fingerprint icon in the bottom left corner). For further details, please see Individual configuration and our Privacy notice.
Impressum | DatenschutzThe settings you specify here are stored in the "local storage" of your device. The settings will be remembered for the next time you visit our online shop. You can change these settings at any time (fingerprint icon in the bottom left corner).
For more information on cookie lifetime and required essential cookies, please see the Privacy notice.
To view YouTube contents on this website, you need to consent to the transfer of data and storage of third-party cookies by YouTube (Google). This allows us to improve your user experience and to make our website better and more interesting. Without your consent, no data will be transferred to YouTube. However, you will also not be able to use the YouTube services on this website.
To view Vimeo contents on this website, you need to consent to the transfer of data and storage of third-party cookies by Vimeo.. This allows us to improve your user experience and to make our website better and more interesting. Without your consent, no data will be transferred to Vimeo. However, you will also not be able to use the Vimdeo services on this website.
To submit forms on this page, you need to consent to the transfer of data and storage of third-party cookies by Google. With your consent, reCAPTCHA, a Google service to avoid spam messages via contact forms, will be embedded. This service allows us to provide our customers with a safe way to contact us via online forms. At the same time, the service prevents spam bots from compromising our services. After you gave your permission, you might be asked to answer a security prompt to send the form. If you do not consent, unfortunately you cannot use the form. Please contact us in a different way.
This is a web analytics service.
Data collected: anonymized IP address, date and time of the visit, usage data, click path, app updates, browser information, device information, JavaScript support, pages visited, referrer URL, location information, purchase activity, widget interactions
Analyse
Processing company:Google Ireland Ltd, Gordon House, Barrow Street, Dublin 4,IE
Terms of use: LinkWould you like to see these contents? Activate the desired contents for one session only or allow the website to remember these settings. Once you have given your consent, the third-party data can be loaded. For this, third-party cookies might be stored on your device. You can change these settings at any time (fingerprint icon in the bottom left corner). For further details, please see the Privacy notice.